Университетска многопрофилна болница за активно лечение „Канев“ АД – Русе е най-старата гражданска болница в България.

During the past decade, MHAT - Ruse, AD conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 18 clinical trials were completed, i.e. on average, 58.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 17 clinical trials were completed. i.e. 154.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT - Ruse, AD" #1 sponsor was "Pfizer" with 6 trials, followed by "Celgene" with 5 trials sponsored, "Galapagos NV" with 3 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT - Ruse, AD" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "KCAS Bio" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "MHAT - Ruse, AD" are "Ulcerative Colitis" (6 trials), "Rheumatoid Arthritis" (5 trials), "Crohn Disease" (4 trials), "Bladder Cancer" (2 trials) and "Psoriatic Arthritis" (2 trials). Many other conditions were trialed in "MHAT - Ruse, AD" in a lesser frequency.

Most popular intervention types in "MHAT - Ruse, AD" are "Drug" (32 trials), "Other" (6 trials), "Biological" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Etrasimod" (4 trials), "Ozanimod" (3 trials), "Adalimumab" (2 trials) and "Etrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "MHAT - Ruse, AD" are 32 trials for "All" genders.

Currently, there are NaN active trials in "MHAT - Ruse, AD". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in MHAT - Ruse, AD, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in MHAT - Ruse, AD, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".